Parkinson's disease (PD) is the second most common neurodegenerative disease and is characterized by the degeneration of dopamine neurons in the substantia nigra and the formation of alpha-synuclein aggregates called Lewy bodies. While aging is the greatest risk factor for the development of PD, the role of aging in the pathogenesis of PD is not known and it is currently uncertain why the symptoms take many decades to develop when the disease-causing mutations can be present from birth. We hypothesize that there are specific changes that take place during the aging process that make cells susceptible to disease-causing mutations that are well-tolerated at younger ages. If so, then interventions that increase lifespan should be beneficial in the treatment of PD. To test this hypothesis, we used the powerful genetics of C. elegans, as this worm has been used extensively in aging research. We crossed transgenic worm models of PD expressing either human mutant alpha-synuclein (A53T) or LRRK2 (G2019S) with the long-lived insulin-IGF1 receptor mutant,
daf-2. The
daf-2 mutation increased the lifespan of both PD mutants. The resulting increase in lifespan ameliorated the degeneration of dopamine neurons in both PD strains and rescued deficits in the dopamine-dependent behaviors including basal slowing and ethanol avoidance. Increasing lifespan through
daf-2 mutation also delayed aggregation in a worm model of PD expressing alpha-synuclein in the body wall muscle. Examining potential mechanisms by which delaying aging reduced dopamine neuron loss, we found that the
daf-2 mutation rescued deficits in resistance to different stresses that were present in the PD mutant worms. Overall, we show that delaying aging through decreasing the activity of the insulin-IGF1 signaling pathway is beneficial in animal models of PD.